Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Zweegman, S, Stege, CAM, Haukas, E, Schjesvold, FH, Levin, M-D, Waage, A, Leys, RBL, Klein, SK, Szatkowski, D, Axelsson, P, Hieu Do, T, Knut-Bojanowska, D, van der Spek, E, Svirskaite, A, Klostergaard, A, Salomo, M, Blimark, C, Ypma, PF, Mellqvist, U-H, Poddighe, PJ, Stevens-Kroef, M, van de Donk, NWCJ, Sonneveld, P, Hansson, M, van der Holt, B & Abildgaard, N 2020, 'Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial', Haematologica, bind 105, nr. 12, s. 2879-2882. https://doi.org/10.3324/haematol.2019.240374

APA

Zweegman, S., Stege, C. A. M., Haukas, E., Schjesvold, F. H., Levin, M-D., Waage, A., Leys, R. B. L., Klein, S. K., Szatkowski, D., Axelsson, P., Hieu Do, T., Knut-Bojanowska, D., van der Spek, E., Svirskaite, A., Klostergaard, A., Salomo, M., Blimark, C., Ypma, P. F., Mellqvist, U-H., ... Abildgaard, N. (2020). Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica, 105(12), 2879-2882. https://doi.org/10.3324/haematol.2019.240374

CBE

Zweegman S, Stege CAM, Haukas E, Schjesvold FH, Levin M-D, Waage A, Leys RBL, Klein SK, Szatkowski D, Axelsson P, Hieu Do T, Knut-Bojanowska D, van der Spek E, Svirskaite A, Klostergaard A, Salomo M, Blimark C, Ypma PF, Mellqvist U-H, Poddighe PJ, Stevens-Kroef M, van de Donk NWCJ, Sonneveld P, Hansson M, van der Holt B, Abildgaard N. 2020. Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica. 105(12):2879-2882. https://doi.org/10.3324/haematol.2019.240374

MLA

Vancouver

Author

Zweegman, Sonja ; Stege, Claudia A M ; Haukas, Einar ; Schjesvold, Fredrik H ; Levin, Mark-David ; Waage, Anders ; Leys, Rineke B L ; Klein, Saskia K ; Szatkowski, Damian ; Axelsson, Per ; Hieu Do, Trung ; Knut-Bojanowska, Dorota ; van der Spek, Ellen ; Svirskaite, Asta ; Klostergaard, Anja ; Salomo, Morten ; Blimark, Celine ; Ypma, Paula F ; Mellqvist, Ulf-Henrik ; Poddighe, Pino J ; Stevens-Kroef, Marian ; van de Donk, Niels W C J ; Sonneveld, Pieter ; Hansson, Markus ; van der Holt, Bronno ; Abildgaard, Niels. / Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. I: Haematologica. 2020 ; Bind 105, Nr. 12. s. 2879-2882.

Bibtex

@article{29d706d41e3d49f99a2ba8ae64379299,
title = "Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial",
author = "Sonja Zweegman and Stege, {Claudia A M} and Einar Haukas and Schjesvold, {Fredrik H} and Mark-David Levin and Anders Waage and Leys, {Rineke B L} and Klein, {Saskia K} and Damian Szatkowski and Per Axelsson and {Hieu Do}, Trung and Dorota Knut-Bojanowska and {van der Spek}, Ellen and Asta Svirskaite and Anja Klostergaard and Morten Salomo and Celine Blimark and Ypma, {Paula F} and Ulf-Henrik Mellqvist and Poddighe, {Pino J} and Marian Stevens-Kroef and {van de Donk}, {Niels W C J} and Pieter Sonneveld and Markus Hansson and {van der Holt}, Bronno and Niels Abildgaard",
year = "2020",
month = dec,
doi = "10.3324/haematol.2019.240374",
language = "English",
volume = "105",
pages = "2879--2882",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Fondazione/Ferrata Storti",
number = "12",

}

RIS

TY - JOUR

T1 - Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

AU - Zweegman, Sonja

AU - Stege, Claudia A M

AU - Haukas, Einar

AU - Schjesvold, Fredrik H

AU - Levin, Mark-David

AU - Waage, Anders

AU - Leys, Rineke B L

AU - Klein, Saskia K

AU - Szatkowski, Damian

AU - Axelsson, Per

AU - Hieu Do, Trung

AU - Knut-Bojanowska, Dorota

AU - van der Spek, Ellen

AU - Svirskaite, Asta

AU - Klostergaard, Anja

AU - Salomo, Morten

AU - Blimark, Celine

AU - Ypma, Paula F

AU - Mellqvist, Ulf-Henrik

AU - Poddighe, Pino J

AU - Stevens-Kroef, Marian

AU - van de Donk, Niels W C J

AU - Sonneveld, Pieter

AU - Hansson, Markus

AU - van der Holt, Bronno

AU - Abildgaard, Niels

PY - 2020/12

Y1 - 2020/12

U2 - 10.3324/haematol.2019.240374

DO - 10.3324/haematol.2019.240374

M3 - Journal article

C2 - 33256392

VL - 105

SP - 2879

EP - 2882

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 12

ER -

ID: 62109007